Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 16860701)

1.

Bronchiolitis.

Smyth RL, Openshaw PJ.

Lancet. 2006 Jul 22;368(9532):312-22. Review.

PMID:
16860701
2.

Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.

Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD.

J Manag Care Pharm. 2010 Jan-Feb;16(1):15-22.

3.

Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.

Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.

Pediatrics. 2004 Dec;114(6):1612-9.

PMID:
15574623
4.

Prevention of respiratory syncytial virus infection in infants.

Handforth J, Sharland M, Friedland JS.

BMJ. 2004 May 1;328(7447):1026-7. No abstract available.

7.

Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?

Hashmi NA, Cosgrove JF, MacMahon P.

Ir Med J. 2000 Dec;93(9):284.

PMID:
11209917
8.

Utilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants.

Curtiss FR, Fairman KA.

J Manag Care Pharm. 2010 Jan-Feb;16(1):59-66. No abstract available.

9.

Respiratory syncytial virus immune globulin: decisions and costs.

Barton LL, Grant KL, Lemen RJ.

Pediatr Pulmonol. 2001 Jul;32(1):20-8.

PMID:
11416872
10.

Economic analysis of palivizumab in infants with congenital heart disease.

Yount LE, Mahle WT.

Pediatrics. 2004 Dec;114(6):1606-11.

PMID:
15574622
11.

Respiratory syncytial virus bronchiolitis.

Leung AK, Kellner JD, Davies HD.

J Natl Med Assoc. 2005 Dec;97(12):1708-13. Review.

12.

Does respiratory syncytial virus subtype influences the severity of acute bronchiolitis in hospitalized infants?

Papadopoulos NG, Gourgiotis D, Javadyan A, Bossios A, Kallergi K, Psarras S, Tsolia MN, Kafetzis D.

Respir Med. 2004 Sep;98(9):879-82.

PMID:
15338801
13.

[Current news about epidemiology of syncytial respiratory virus infection].

Palumbo E.

Recenti Prog Med. 2008 May;99(5):237-9. Italian.

PMID:
18581965
14.

Prevention of respiratory syncytial virus infection with palivizumab.

Thomas M, Bedford-Russell A, Sharland M.

Monaldi Arch Chest Dis. 2000 Aug;55(4):333-8. Review.

PMID:
11057088
15.

Rhinovirus-associated wheezing in infancy: comparison with respiratory syncytial virus bronchiolitis.

Korppi M, Kotaniemi-Syrjänen A, Waris M, Vainionpää R, Reijonen TM.

Pediatr Infect Dis J. 2004 Nov;23(11):995-9.

PMID:
15545853
16.

Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.

Prais D, Schonfeld T, Amir J; Israeli Respiratory Syncytial Virus Monitoring Group.

Pediatrics. 2003 Sep;112(3 Pt 1):548-52.

PMID:
12949282
17.

Recurrent wheezing after respiratory syncytial virus or non-respiratory syncytial virus bronchiolitis in infancy: a 3-year follow-up.

Valkonen H, Waris M, Ruohola A, Ruuskanen O, Heikkinen T.

Allergy. 2009 Sep;64(9):1359-65. doi: 10.1111/j.1398-9995.2009.02022.x. Epub 2009 Mar 23.

PMID:
19416146
18.

Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.

Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, Gouyon JB; Burgundy Perinatal Network.

Pediatr Pulmonol. 2007 Mar;42(3):189-92.

PMID:
17243184
19.

A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.

Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ.

J Manag Care Pharm. 2010 Jan-Feb;16(1):46-58. Review.

20.

Response to respiratory synctial virus.

Hampp C, Winterstein AG.

South Med J. 2008 Feb;101(2):212-3; author reply 213-4. doi: 10.1097/SMJ.0b013e3181611d5f. No abstract available.

PMID:
18364631
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk